Pharmacokinetic properties of platinium derivatives;Pharmacocinétique clinique comparative des dérivés du platine

Bulletin du Cancer

Volumn 88, Issue SPEC. ISS., 2001, Pages

  Boisdron Celle, M ^a   Lebouil, A ^a   Allain, P ^a   Gamelin, E ^a  

^a CENTRE PAUL PAPIN   (France)

Author keywords

Oxaliplatin; Pharmacokinetics; Platinum derivatives

Indexed keywords

ALBUMIN; CISPLATIN; CYCLOHEXANE DERIVATIVE; CYSTEINE; DRUG METABOLITE; FLUOROURACIL; GLUTATHIONE; IMMUNOGLOBULIN; METHIONINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN; THIOL GROUP; ANTINEOPLASTIC AGENT; CARBOPLATIN; PLATINUM COMPLEX;

ANEMIA; COVALENT BOND; CREATININE CLEARANCE; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ERYTHROCYTE; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; PHARMACODYNAMICS; PLASMA CLEARANCE; REVIEW; URINARY EXCRETION; BLOOD; DRUG INTERACTION; HALF LIFE TIME; KIDNEY; METABOLISM;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG INTERACTIONS; ERYTHROCYTES; HALF-LIFE; HUMANS; KIDNEY; ORGANOPLATINUM COMPOUNDS;

EID: 0034827506     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
2. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin
3. Pharmacokinetics of cis-diammine-1, 1-cyclobutanecicarboxylate platinum (II) in patients with normal and impaired renal function
4. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function
5. Long-term pharmacokinetic behaviour of platinum after cisplatin administration
6. Non linear renal clearance of ultrafiltrable platinum in patients treated with cis-diamminedichloroplatinum(II)
7. Cisplatin pharmacokinetics using a five day schedule during repeated courses of chemotherapy in germ cell tumors
8. Reduced ability to clear ultrafiltrable platinum with repeated courses of cisplatin
9. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluoro-uracil to colorectal cancer patients
10. Creatinine clearance as a predictor of ultrafiltrable platinum deposition in cancer patients treated with cisplatin : Relationship between peak ultrafiltrable platinum plasma levels and nephrotoxicity
11. Long term retention and distribution of platinum in animals after cisplatin administration
12. Increased tissue deposition and decreased excretion of platinum following administration of cisplatin to cisplatin-pretreated animals
13. Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity
14. Pharmacokinetic and toxicity evaluation of 5-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients
15. Correlation between free platinum AUC and total platinum measurement 24 h after IV bolus injection of cisplatin in humans
16. In vitro plasma binding of some second generation antitumor platinum complexes
17. Reactions of cisplatin with human plasma and plasma fractions
18. Distribution of cis-platin in blood
19. Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin
20. Kinetic studies of the reactivity between cisplatin and its monoaquo species with L-methionine
21. Early biotransformation of oxaliplatin following its intravenous administration to cancer patients
22. Plasma and cerebrospinal fluid pharmacokinetics of carboplatin and cisplatin
23. Determination of unbound platinum after oxaliplatin administration : Comparison of currently available methods and influence of various parameters
24. Methionine dependence of tumor cells : Programmed cell survival
25. In vitro stability, plasma protein binding and blood partitioning of C14-carboplatin
26. Platinum levels in human erythrocytes following intravenous administration of cisplatin : Importance of erythrocytes as a distribution site for platinum species
27. Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
28. Carboplatin dosage : Prospective evaluation of a simple formula based on renal function
29. Ring opened adducts of the anticancer drug carboplatin with sulfur amino acids
30. Sequences of taxol and cisplatin : A phase I and pharmacologic study
31. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
32. Reduced platelet toxicity with combination carboplatin and paclitaxel : Pharmacodynamic modulation of carboplatin associated thrombocytopenia
33. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and dose sequencing study in patients with non-small-cell lung cancer
34. Metabolism of docetaxel by human cytochrom P450 : Interactions with paclitaxel and other antineoplastic drugs
35. Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes
36. Metabolic basis of the synergistic antitumor activities of 5-fluoro-uracil and cisplatin in rodent tumor models in vivo